Enliven Therapeutics Stock Initiated at Overweight by Morgan Stanley
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowMorgan Stanley has initiated coverage of Enliven Therapeutics (ELVN) with an 'overweight' rating. This designation suggests a positive outlook for the stock's performance relative to its peers. Investment firms typically assign overweight ratings to indicate that they expect a company's share price to outperform the market average. This rating can influence investor decisions and may lead to increased buying activity in the stock.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Morgan Stanley (MS)
Morgan Stanley is a leading global investment bank and wealth manager.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier MS news
- Gold Prices Pull Back; Morgan Stanley Sees Strong Reasons to Hold
- Judge to Decide on White House Ban Extension by CNN and MS NOW
- Morgan Stanley Asia Deals Highlighted in Missent Email Attachment
- Judge Restores CNN, MS NOW, Politico Access to White House
- Imax (IMAX) Stock Rated A Buy by Morgan Stanley
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
